Linezolid Placebo

DRUG4 trials

Sponsors

Furiex Pharmaceuticals, Inc, GlaxoSmithKline, Durata Therapeutics Inc., an affiliate of Allergan plc, Debiopharm International SA

Conditions

Bacterial InfectionsCommunity Acquired PneumoniaComplicated Skin and Skin Structure InfectionsSkin Infections, Bacterial

Phase 2

Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)

CompletedNCT01128530

Furiex Pharmaceuticals, IncComplicated Skin and Skin Structure Infections

Start: 2010-06-30End: 2011-01-31Updated: 2011-12-16

GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection

CompletedNCT01209078

GlaxoSmithKlineSkin Infections, Bacterial

Start: 2010-08-17End: 2011-01-18Updated: 2017-12-04

Study of Debio 1450 for Bacterial Skin Infections

CompletedNCT02426918

Debiopharm International SABacterial Infections

Start: 2015-05-31End: 2016-09-30Updated: 2019-11-13

Phase 3

A P3 Comparator Trial in Community Acquired Bacterial Pneumonia

WithdrawnNCT02269644

Durata Therapeutics Inc., an affiliate of Allergan plcCommunity Acquired Pneumonia

Start: 2015-11-30End: 2016-12-31Updated: 2016-01-22

Related Papers

Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid.

2020-09-2146 citations

Safety, Tolerability, and Efficacy of GSK1322322 in the Treatment of Acute Bacterial Skin and Skin Structure Infections

Antimicrobial Agents and Chemotherapy2014-08-1940 citations